🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)

    Seqirus (Australia) Pty Ltd

    Influenza

    phase 3 mab completed

    1 trial

  2. MIDAZOLAM , CEDACONDA 100 % V/V, liquide pour inhalation par vapeur, PROPOFOL

    Pari Pharma GmbH

    Adult patients with severe cardiogenic shock on venoarterial ECMO support for less than 24 hours.

    phase 3 small molecule active

    1 trial

  3. MIDAZOLAM , PROPOFOL , ROCURONIUM BROMIDE , Cipepofol Injectable Emulsion, FENTANYL , SEVOFLURANE , PROPOFOL

    Lacuna Pharma Pty Ltd

    General anaesthesia

    phase 3 small molecule active

    1 trial

  4. MIDAZOLAM, DEXMEDETOMIDINE EVER PHARMA 100 microgrammes/mL, solution à diluer pour perfusion

    Pari Pharma GmbH

    Very preterm neonate (gestational age at birth < 32 WG) with corrected gestational age <45 WG) with indication for sedation in the context of invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  5. MIDOSTAURIN, ARACYTIN 500 mg/10 ml Polvere e Solvente per Soluzione Iniettabile, DAUNORUBICIN HYDROCHLORIDE

    Fondazione Telethon ETS

    Acute Myeloid Leukemia (LMA) with FLT3 mutation

    phase 3 small molecule active

    1 trial

  6. MIE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Carcinoma

    phase 3 other active

    1 trial

  7. MINJUVI 200 mg powder for concentrate for solution for infusion

    Incyte

    Immune-mediated thrombocytopenia, Autoimmune thrombocytopenia, Autoimmune hemolytic anemia

    phase 3 small molecule active

    1 trial

  8. MITAPIVAT, MITAPIVAT, Placebo for AG-348, MITAPIVAT, MITAPIVAT

    Lacuna Pharma Pty Ltd

    Pyruvate Kinase Deficiency

    phase 3 small molecule active

    1 trial

  9. MITAPIVAT, Placebo for MITAPIVAT, MITAPIVAT, MITAPIVAT, MITAPIVAT

    Lacuna Pharma Pty Ltd

    Pyruvate Kinase Deficiency

    phase 3 small molecule active

    1 trial

  10. MITAPIVAT, Placebo for Mitapivat

    Lacuna Pharma Pty Ltd

    Transfusion-Dependent Alpha- or Beta-Thalassemia

    phase 3 small molecule active

    1 trial

  11. MITOMYCIN , JNJ-42756493, GEMCITABINE

    Janssen-Cilag International N.V.

    High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations

    phase 3 small molecule active

    1 trial

  12. MK-1022, CAPECITABINE , PACLITAXEL , TRASTUZUMAB DERUXTECAN , PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN , DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL

    Merck Sharp and Dohme

    Hormone receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  13. MK-2870, CAPECITABINE , CYCLOPHOSPHAMIDE , PACLITAXEL , DEXAMETHASONE , DOXORUBICIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, EPIRUBICIN , CARBOPLATIN

    Merck Sharp and Dohme

    Breast Cancer: triple negative breast cancer (TNBC) and hormone receptor (HR)-low positive/HER2 negative breast cancer

    phase 3 small molecule active

    1 trial

  14. MK-3543, HYDROXYCARBAMIDE , Placebo for hydroxycarbamide, MK-3543, MK-3543, MK-3543, Placebo for Bomedemstat

    Merck Sharp and Dohme

    Essential thrombocythemia

    phase 3 small molecule active

    1 trial

  15. MK-8527

    Merck KGaA, Darmstadt, Germany

    Human Immunodeficiency Virus (HIV)

    phase 3 small molecule active

    1 trial

  16. MORPHINE , PENTHROX 99,9%, liquide pour inhalation par vapeur de 3 mL

    Pari Pharma GmbH

    Acute Myocardial Infarction

    phase 3 small molecule active

    1 trial

  17. MORPHINE SULFATE, KETAMINE, FENTANYL CITRATE, SODIUM CHLORIDE, SODIUM CHLORIDE

    Pari Pharma GmbH

    urgency, limb injuries

    phase 3 small molecule active

    1 trial

  18. MPs

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hematological Diseases

    phase 3 mab active

    1 trial

  19. MT-7117 Formulation Code C

    Lacuna Pharma Pty Ltd

    Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

    phase 3 small molecule active

    1 trial

  20. MT-7117 Formulation Code C, MT-7117 Placebo

    Lacuna Pharma Pty Ltd

    Erythropoietic Protoporphyria or X-Linked Protoporphyria

    phase 3 small molecule active

    1 trial

  21. MTX

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gestational Trophoblastic Tumor

    phase 3 small molecule active

    1 trial

  22. MYCOPHENOLATE MOFETIL, ETOPOSIDE, DURVALUMAB, INFLIXIMAB, SILTUXIMAB, Tarlatamab, CARBOPLATIN, Tarlatamab

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.

    phase 3 small molecule active

    1 trial

  23. MYCOPHENOLATE MOFETIL, IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Adult patients (age ≥18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), unresectable Stage IV, and who are chemotherapy-naïve.

    phase 3 small molecule active

    1 trial

  24. MYCOPHENOLIC ACID, -, MYCOPHENOLATE MOFETIL, VAY736, TENOFOVIR ALAFENAMIDE , ENTECAVIR , TENOFOVIR DISOPROXIL

    Novartis Pharmaceuticals

    Lupus nephritis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources